Dentons Advises SAB BIO on Public Offering

Dentons advised SAB BIO on its US$85 million public offering, providing strategic legal counsel to support the company's access to the public capital markets. The transaction is expected to fund the continued development of SAB BIO's clinical stage product candidate through ongoing and planned clinical trials.

Serving as issuer's counsel, Dentons advised on an offering structure that included both common stock and pre-funded warrants to address investor and regulatory considerations, supporting the full securities package sold in the transaction and reflecting the firm's experience in complex, high profile capital markets transactions.

Dentons was pleased to support SAB BIO with a team led by partners Ilan Katz, Brian Lee, Grant Levine, and managing associate Zachary Weiss, all based in New York.

About Dentons

Redefining possibilities. Together, everywhere. For more information visit dentons.com